Zynerba Pharmaceuticals Inc Remains Bullish
The first half of 2019 was very kind to the markets in general, with all of the major indices trading near or at record levels. And cannabis stocks continue to be one of the best plays.
The top cannabis stock in the first half of 2019 isn’t one of the more common names you hear being discussed around the water cooler. Nevertheless, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) saw its share price advance 355% in the first half of 2019, rising from a $2.98 open price on January 2 to a closing price of $13.55 on June 30.
Zynerba is a clinical-stage specialty pharmaceutical company developing transdermal (under the skin) cannabinoid therapies to treat rare conditions.
As a development-stage biotech company, earnings are not nearly as important as positive drug trials, patents, and